Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  ADJUVANT
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

The new approaches in the area of vaccines development and administer

100%
Kapusta J.
Biotechnologia
|
1999
|
issue 3
94-105
EN
Overviews of current vaccine development in respects to the idea of elaborate vaccines simple to handling and administer. The progress made recently in technologies concerning adjuvants, antigen formulation and vaccine delivery systems has been summarized. Special attention has been focused on mucosal way of vaccine application and orally induced immunity as well newest achievements in the technology using plant as vaccine carriers.
2

The search for novel adjuvants for early life vaccinations: can ?danger? motifs show us the way?

100%
Kovarik J., Siegrist C.-A.
Archivum Immunologiae et Therapiae Experimentalis
|
2001
|
vol. 49
|
issue 3
209-215
EN
Potent but safe adjuvants are required to circumvent the many limitations of the newborn immune system to induce rapidly effective and long lasting immunity to subunit vaccines. By the use of pattern recognition receptors, antigen-presenting cells (APC) can very efficiently be activated by ?danger? motifs expressed by various pathogens. APC activated by ?danger? motifs, such as immunostimulatory sequences of bacterial DNA, can not only transmit the activation signal from the innate immunity to the adaptive compartment, but also shape the antigen-specific immune responses. Molecules or compounds expressing ?danger? motifs could, therefore, be considered for use as adjuvants for subunit vaccines. In this review, the authors discuss the promises and potential drawbacks that such novel adjuvants could hold for their use in experimental and clinical early life vaccinations.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.